The prognostic value of weight and body composition changes in patients with non-small-cell lung cancer treated with nivolumab

Juliette H.R.J. Degens, Anne Marie C. Dingemans, Anna C.H. Willemsen, Hester A. Gietema, Daan P. Hurkmans, Joachim G. Aerts, Lizza E.L. Hendriks, Annemie M.W.J. Schols*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)
3 Downloads (Pure)

Abstract

Background: It is not well known to what extent effectiveness of treatment with immune checkpoint inhibitors in stage IV non-small-cell lung cancer (NSCLC) is influenced by weight loss and changes in body composition. Therefore, the goal of this study was to evaluate body composition changes in relation to early weight change and overall survival (OS) in stage IV NSCLC patients treated with second-line nivolumab. Methods: All patients with stage IV NSCLC, who were treated with second-line nivolumab between June 2015 and December 2018 at Maastricht University Medical Center, were evaluated. Skeletal muscle mass (SMM), visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) were assessed at the first lumbar level on computed tomography images obtained before initiation of nivolumab and at week 6 of treatment. The contribution of changes in body weight (defined as >2% loss), SMM, VAT, and SAT to OS was analysed by Kaplan–Meier method and adjusted for clinical confounders in a Cox regression analysis. The results from the study cohort were validated in another Dutch cohort from Erasmus Medical Center, Rotterdam. Results: One hundred and six patients were included in the study cohort. Loss of body weight of >2% at week 6 was an independent predictor for poor OS (hazard ratio 2.39, 95% confidence interval 1.51–3.79, P < 0.001) when adjusted for gender, >1 organ with metastasis, pretreatment hypoalbumenaemia, and pretreatment elevated C-reactive protein. The result was confirmed in the validation cohort (N = 62). Loss of SMM as a feature of cancer cachexia did not significantly predict OS in both cohorts. Significant (>2%) weight loss during treatment was reflected by a significant loss of VAT and SAT, while loss of SMM was comparable between weight-stable and weight-losing patients. Conclusions: Weight loss, characterized by loss of subcutaneous and visceral adipose tissues, at week 6 of treatment with nivolumab, is a significant poor prognostic factor for survival in patients with Stage IV NSCLC.

Original languageEnglish
Pages (from-to)657-664
Number of pages8
JournalJournal of Cachexia, Sarcopenia and Muscle
Volume12
Issue number3
Early online date5 May 2021
DOIs
Publication statusPublished - Jun 2021

Bibliographical note

Funding Information:
J.H.R.J.D., A.C.H.W., H.A.G., D.P.H., and A.M.W.J.S. have no conflicts of interest. A‐M.C.D. reports personal fees from advisory boards BMS, MSD, Roche, Eli Lilly, Takeda, Pfizer, and Boehringer Ingelheim, outside the submitted work. L.E.L.H. reports other fees from Boehringer Ingelheim, BMS, Roche, and AstraZeneca; grants from Roche and Boehringer Ingelheim; and personal fees from Quadia, outside the submitted work. J.G.A. reports personal fees and non‐financial support from MSD and personal fees from BMS, Boehringer Ingelheim, Amphera, Eli Lilly, Takeda, Bayer, Roche, and AstraZeneca, outside the submitted work. In addition, J.G.A. has a patent allogeneic tumour cell lysate licenced to Amphera, a patent combination immunotherapy in cancer pending, and a patent biomarker for immunotherapy pending.

Publisher Copyright:
© 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders

Fingerprint

Dive into the research topics of 'The prognostic value of weight and body composition changes in patients with non-small-cell lung cancer treated with nivolumab'. Together they form a unique fingerprint.

Cite this